Chapter 28 - Uncertainties in endocrine substitution therapy for central endocrine insufficiencies: growth hormone deficiency
Introduction
The growth hormone (GH) deficiency syndrome is associated with several metabolic abnormalities (Cuneo et al., 1992, Carroll and Christ, 1998, Maison et al., 2004), and it has been postulated that the increased cardiovascular morbidity and mortality recorded in GH-deficient (GHD) patients may be related to the missing metabolic effects of GH (Rosén and Bengtsson, 1990, Bülow et al., 1997). In addition, it has been suggested that the adult GHD phenotype shares features of the metabolic syndrome, such as abdominal obesity, dyslipidemia, and insulin resistance, thus a cluster of risk factors for cardiovascular disease (CVD) and type 2 diabetes mellitus (Ford, 2005, Cornier et al., 2008). GH has a positive effect on body composition, with increased lean mass and reduced fat mass, and with a reduction particularly in waist measurements and a favorable effect on lipid levels (Maison et al., 2004). Many of the traditional CVD risk factors show improvements after GH therapy, which might decrease CVD risk in these patients and improve longevity. In particular, if patients with newly developed GHD received early GH replacement, the negative effects of GHD could possibly be avoided.
GH affects linear growth and is important for skeletal development in young adults and for bone turnover in adult skeletal tissue (Ohlsson et al., 1998). Reduced bone mineral density (BMD) has been recorded both in patients with isolated GHD and in those with multiple pituitary deficiencies, indicating that GHD per se is, at least in part, responsible for the low BMD in both types (De Boer et al., 1994, Holmes et al., 1994). There are, however, contradictory results from studies in adult onset GHD showing both normal BMD, particularly in older subjects (Toogood et al., 1997, Fernholm et al., 2000), and low BMD (Rosén et al., 1993, Degerblad et al., 1995). In contrast, in patients with childhood-onset GHD (Kaufman et al., 1992, O’Halloran et al., 1993, De Boer et al., 1994) there seems to be a clear reduction in BMD, which may illustrate the potential role of GH in the acquisition of peak bone mass (De Boer et al., 1994).
These matters are, however, more complicated, as hypopituitary patients with GHD appear in several phenotypes due to different background diagnoses. Furthermore, GHD is not the only risk factor for CVD or low BMD in these patients. This notion is based on the observation that the effect of complete hormone substitutions, including GH therapy, differs depending on the phenotypes of hypopituitary patients. However, these phenotypes are not clear-cut and not absolute in individual patients as patients may transit between the different phenotypes over time due to extension of the pathology and/or the effects of treatment (surgery and/or radiotherapy). Moreover, in clinical practice patients with similar pituitary diseases may fall into different categories of GHD and may even transit from one category (e. g., GHD only) to a second category (e.g., GHD with multiple hormone deficiencies).
The purpose of this chapter is to discuss three different phenotypes of hypopituitary patients with GHD, with a focus on CVD risk and bone health:
- 1.
Patients with isolated GHD, e.g., caused by prophylactic cranial radiotherapy for lymphoblastic leukemia in childhood
- 2.
Patients with GHD and multiple hormone deficiencies, caused by a pituitary macroadenoma, treated by surgery
- 3.
Patients with GHD and multiple hormone deficiencies and with hypothalamic involvement caused by a craniopharyngioma.
Section snippets
Cardiovascular risk after acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and constitutes 25% of all childhood cancers. The peak incidence is at the age of 2–4 years. The survival after ALL has improved dramatically during recent decades, and is currently about 85%, which emphasises the importance of long-term treatment complications (Oeffinger et al., 2000). GHD is common after long-term follow-up in survivors of childhood ALL treated with prophylactic cranial radiotherapy (Brennan et al.,
Cardiovascular risk in hypopituitary patients with nonsecreting pituitary macroadenomas
Epidemiologic studies have revealed increased cerebral and cardiovascular mortality in patients with hypopituitarism on conventional hormone treatment but without GH therapy. The greatest increase was seen in cerebrovascular disease (Bülow et al., 1997, Tomlinson et al., 2001), with a more pronounced risk in women (Bülow et al., 1997, Tomlinson et al., 2001), but without gender difference in cardiac mortality (Bülow et al., 1997). These epidemiologic studies included particularly patients with
Cardiovascular risk in patients with a craniopharyngioma
In cohort studies of patients with craniopharyngiomas (CP) the SMR varies from 2.88 to 9.28 (Bülow et al., 1998, Tomlinson et al., 2001, Pereira et al., 2005). In addition, CP patients have a particularly high CVD mortality in comparison to the general population (3–19-fold higher) (Bülow et al., 1998, Tomlinson et al., 2001, Pereira et al., 2005). Women with CP have an even higher risk (Bülow et al., 1998, Pereira et al., 2005).
Patients with hypothalamic involvement by a CP have significantly
General uncertainties of growth hormone therapy
GH therapy of adults has generally been regarded as quite a safe treatment, although concerns remain regarding the potential for cancer risk, as IGF-1 has mitogenic effects on both normal and cancerous cells (Maculty, 1992). In general, GH treatment is contraindicated in the presence of active malignancy. Although GH treatment reduces insulin sensitivity, the worsening of glycemic control has been minimal and transient, and low GH doses may even improve insulin sensitivity. However, GH
Conclusion
If GHD was an isolated entity the metabolic effects of GH therapy could be easily predicted. However, based on different background diagnoses, there are several phenotypes of the hypopituitary patient with GHD. In clinical practice these patients may even transit between the different phenotypes over time due to extension of the pathology and/or the effects of treatments (surgery and/or radiotherapy). Furthermore, hypothalamic involvement, but also hormone substitutions of other pituitary
References (76)
- et al.
Osteoporosis after cranial irradiation for acute lymphoblastic leukemia
J Pediatr
(1990) - et al.
20-year experience in childhood craniopharyngioma
Int J Radiat Oncol Biol Phys
(1993) - et al.
Premature mortality due to cardiovascular disease in hypopituitarism
Lancet
(1990) - et al.
Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults
Int J Radiat Oncol Biol Phys
(2004) - et al.
Association between premature mortality and hypopituitarism
Lancet
(2001) - et al.
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial
JAMA
(2004) Clinical review 162: Cardiovascular Endocrinology 3. An epidemiologist looks at hormones and heart disease in women
J Clin Endocrinol Metab
(2003)- et al.
Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study
J Clin Oncol
(2006) - et al.
Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a review of the literature
Medicine (Baltimore)
(1975) - et al.
Hypothalamic obesity. The autonomic hypothesis and the lateral hypothalamus
Diabetologia
(1981)
Growth hormone status in adults treated for acute lymphoblastic leukaemia in childhood
Clin Endocrinol (Oxf)
Hyperleptinaemia in young adults following cranial irradiation in childhood: growth hormone deficiency or leptin insensitivity?
Clin Endocrinol (Oxf)
A low individualized GH dose in young patients with childhood onset GH deficiency normalized serum IGF-I without significant deterioration in glucose tolerance
Clin Endocrinol (Oxf)
Increased cerebrovascular mortality in patients with hypopituitarism
Clin Endocrinol (Oxf)
Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence
J Clin Endocrinol Metab
Survivors of childhood acute lymphoblastic leukaemia, with radiation-induced GH deficiency, exhibit hyperleptinaemia and impaired insulin sensitivity, unaffected by 12 months of GH treatment
Clin Endocrinol (Oxf)
Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review
J Clin Endocrinol Metab
The metabolic syndrome
Endocr Rev
Morbidity and mortality in patients with craniopharyngioma after surgery
Clin Endocrinol (Oxf)
The growth hormone deficiency syndrome in adults
Clin Endocrinol (Oxf)
The consequences of childhood-onset growth hormone deficiency for adult bone mass
J Bone Miner Res
Reduced bone mineral density in adults with growth hormone (GH) deficiency: increased bone turnover during 12 months of GH substitution therapy
Eur J Endocrinol
Relationship between bone mineral density, leptin and insulin concentration in Brazilian obese adolscents
J Bone Miner Metab
Long-term outcomes for surgically resected craniopharyngiomas
Neurosurgery
Riskfactors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors
J Clin Endocrinol Metab
Effects of weight and body mass index on bone mineral density in men and women: the Framingham study
J Bone Miner Res
Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease
J Clin Endocrinol Metab
Cardiovascular risk, cardiac function, physical activity and quality of life with and without long-term GH therapy in adult survivors of childhood acute lymphoblastic leukaemia
J Clin Endocrinol Metab
Bone loss after childhood acute lymphoblastic leukaemia: an observational study with and without GH therapy
Eur J Endocrinol
Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence
Diabetes Care
Overall and cause-specific mortality in GH-deficient adults on GH replacement
Eur J Endocrinol
Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men
Am J Physiol Endocrinol Metab
Genetic and environmental correlations between age at menarche and bone mineral density at different skeletal sites
Calcif Tissue Int
Leptin and the sympathetic connection of fat to bone. Review
Osteoporos Int
Non-fatal stroke, cardiac disease, and diabetes mellitus in hypopituitary patients on complete hormone replacement including GH
J Clin Endocrinol Metab
Fracture incidence in GH deficient patients on complete hormone replacement including GH
J Bone Miner Res
Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy
Eur J Endocrinol
Reduced energy expenditure and impaired feeding-related signals but not high energy intake reinforces hypothalamic obesity in adults with childhood onset craniopharyngioma
J Clin Endocrinol Metab
Cited by (3)
Novel perspectives on hypothalamic-pituitary dysfunction as a risk factor for non-alcoholic fatty liver disease
2017, Minerva EndocrinologicaNonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma
2015, European Journal of Endocrinology